327 related articles for article (PubMed ID: 16676271)
21. High-throughput and parallel screening methods in asymmetric hydrogenation.
Jäkel C; Paciello R
Chem Rev; 2006 Jul; 106(7):2912-42. PubMed ID: 16836304
[No Abstract] [Full Text] [Related]
22. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
Guo ZR
Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
[TBL] [Abstract][Full Text] [Related]
23. Putting nature back into drug discovery.
Müller-Kuhrt L
Nat Biotechnol; 2003 Jun; 21(6):602. PubMed ID: 12776140
[No Abstract] [Full Text] [Related]
24. Furans, thiophenes and related heterocycles in drug discovery.
Sperry JB; Wright DL
Curr Opin Drug Discov Devel; 2005 Nov; 8(6):723-40. PubMed ID: 16312148
[TBL] [Abstract][Full Text] [Related]
25. Selective optimization of side activities: another way for drug discovery.
Wermuth CG
J Med Chem; 2004 Mar; 47(6):1303-14. PubMed ID: 14998318
[No Abstract] [Full Text] [Related]
26. Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients.
LaPorte TL; Wang C
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):738-45. PubMed ID: 17987525
[TBL] [Abstract][Full Text] [Related]
27. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery.
Wasan KM; Brocks DR; Lee SD; Sachs-Barrable K; Thornton SJ
Nat Rev Drug Discov; 2008 Jan; 7(1):84-99. PubMed ID: 18079757
[TBL] [Abstract][Full Text] [Related]
28. Pharmacophores in drug design and discovery.
Milne GW; Nicklaus MC; Wang S
SAR QSAR Environ Res; 1998; 9(1-2):23-38. PubMed ID: 9517013
[TBL] [Abstract][Full Text] [Related]
29. Compound scale-up at the discovery-development interface.
Nikitenko AA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
[TBL] [Abstract][Full Text] [Related]
30. Natural products in drug discovery.
Harvey AL
Drug Discov Today; 2008 Oct; 13(19-20):894-901. PubMed ID: 18691670
[TBL] [Abstract][Full Text] [Related]
31. Chemical library synthesis using convergent approaches.
Beeler AB; Schaus SE; Porco JA
Curr Opin Chem Biol; 2005 Jun; 9(3):277-84. PubMed ID: 15939329
[TBL] [Abstract][Full Text] [Related]
32. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?
Newman DJ
J Med Chem; 2008 May; 51(9):2589-99. PubMed ID: 18393402
[No Abstract] [Full Text] [Related]
33. Knowledge-based chemoinformatic approaches to drug discovery.
Ghose AK; Herbertz T; Salvino JM; Mallamo JP
Drug Discov Today; 2006 Dec; 11(23-24):1107-14. PubMed ID: 17129830
[TBL] [Abstract][Full Text] [Related]
34. Developing a drug-like natural product library.
Quinn RJ; Carroll AR; Pham NB; Baron P; Palframan ME; Suraweera L; Pierens GK; Muresan S
J Nat Prod; 2008 Mar; 71(3):464-8. PubMed ID: 18257534
[TBL] [Abstract][Full Text] [Related]
35. Timing of analog research in medicinal chemistry.
Fischer J; Gere A
Pharmazie; 2001 Sep; 56(9):675-82. PubMed ID: 11593984
[TBL] [Abstract][Full Text] [Related]
36. Impact of continuous flow chemistry in the synthesis of natural products and active pharmaceutical ingredients.
Souza JM; Galaverna R; Souza AAN; Brocksom TJ; Pastre JC; Souza ROMA; Oliveira KT
An Acad Bras Cienc; 2018; 90(1 Suppl 2):1131-1174. PubMed ID: 29873673
[TBL] [Abstract][Full Text] [Related]
37. Metabolites in safety testing: metabolite identification strategies in discovery and development.
Nedderman AN
Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
[TBL] [Abstract][Full Text] [Related]
38. March of the synthesis machines.
Sanderson K
Nat Rev Drug Discov; 2015 May; 14(5):299-300. PubMed ID: 25924572
[No Abstract] [Full Text] [Related]
39. Unfinished business: target-based drug discovery.
Brown D
Drug Discov Today; 2007 Dec; 12(23-24):1007-12. PubMed ID: 18061878
[TBL] [Abstract][Full Text] [Related]
40. Forging synergies in drug discovery.
Nat Chem Biol; 2008 Feb; 4(2):83. PubMed ID: 18202672
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
